BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

0.00

BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ: ORKA) with a Buy and maintains $151 price target.